Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
about
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressantsThe gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patientsProgress towards the integration of pharmacogenomics in practicePharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis.Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Antiplatelet drug interactions with proton pump inhibitorsHydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian populationCytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care.Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsPharmacogenomics of antimicrobial agents.Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.Personalizing medicine with clinical pharmacogeneticsIdentification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepineMulti-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family.Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase contentCytochrome P450 Isoforms in the Metabolism of Decursin and Decursinol Angelate from Korean Angelica.CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignanciesPharmacogenetics and cardiovascular disease--implications for personalized medicineEfavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Regulatory polymorphisms in CYP2C19 affecting hepatic expressionIdiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal.Transcriptional regulation and pharmacogenomics.Pharmacogenomics of the triazole antifungal agent voriconazole.Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism.Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Efficacy and safety of current drug therapies for invasive aspergillosis.Pain, analgesia and genetics.
P2860
Q24610169-8ED6CD63-BADD-4A8D-870F-F2F6F802FF2DQ26996594-7FB8204B-9526-4AAF-8A7C-8117366E3B5FQ28652270-01632FB2-A133-4C4D-B62E-C2A1A6F3A24DQ33653925-AE112F1C-E76C-4AAF-A259-9ADA60A6C07BQ33704998-BC345E88-F63D-435E-9724-B302C3E3D5D6Q33849298-0C93FC29-7BC3-42A3-8E54-21B0D54372D0Q33948811-764F3BA6-8C52-49E5-A3F2-438D77F266B4Q34706677-7DB0D90F-177F-4C95-8C9E-4358A7CC942CQ34975032-5F289FC5-8022-416F-979F-F932826B8171Q34976487-3CBC314C-9BD7-410B-A2D7-504DED838137Q34977413-F4B710ED-2E71-4575-AB15-E979CF77CACFQ35058455-0C5BA879-CB2D-4771-8665-3404AB3F11D0Q35074952-C198BF8F-7393-4093-AAA5-50B1B00906D2Q35086478-1B7E77D2-BA70-4B5D-8D49-F41CB35AB05DQ35605304-6DB20C36-92E4-457F-A7FD-1BA95A60CF5AQ35718630-A7B13F9D-F4E7-4A06-8C6E-77B74AB12465Q35791989-527CCB98-9A99-4B8E-AB95-CE5622B70962Q35846595-F9AE9DBC-04B5-46A2-9895-C981472DC216Q35897778-E2F2F1BF-A073-416D-A197-7809AE4AEC84Q35952367-8DA871C5-DBE0-42D4-84FE-FDC6CC82C9FFQ36088030-9ADF0B8F-8EED-4B9A-B4C2-949D9E5DA21FQ36094919-DA97B93B-6A5A-4164-BAB3-9463BA42F1CCQ36307008-3F86C43C-64C0-4A5A-BB9D-1853D350EAC9Q36441503-AB8651F7-6135-43CF-910A-F08EB8B77F5FQ36643041-4541443D-91E8-4FF9-B1A2-EF133FD14E07Q36915336-132F33B2-A8F1-4927-932E-D69D820B961DQ36962516-CE5F84A2-914B-4BC8-BA2B-E0571DF564CBQ36969780-DB418087-50DC-4DE6-A150-99F79054D38BQ36974672-4451E178-6D96-4E54-B199-D51775B9FB10Q37086418-331662CC-CB69-47A0-B939-7D0B959220D1Q37127419-80FFF469-2D9C-46A5-A357-FFC4276C2C42Q37590883-10DDA363-1669-4007-9A48-C69AE25A2D7DQ37599633-0AC9FC45-7945-4C71-8186-6181B7009672Q37880878-65860837-F220-473D-9CF6-4C3A15046969Q37892536-33AFC277-AD3B-4C80-A3B4-FDBF9B5D1E4BQ37898706-1BC988ED-6961-4ED9-8AB7-E8D7D8A36B47Q37910837-57163D86-FF6E-4883-93F3-EB5766B7AE57Q37923969-D2C5D1B5-9366-4AEC-8AFE-439B9AF5E175Q37944001-0A002DA1-CCA4-4CED-A40A-34F1331F8493Q37944353-230A87DD-ADC4-46FD-8341-7A0B726CBBB3
P2860
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacogenetics of CYP2C19: f ...... ns of a new variant CYP2C19*17
@ast
Pharmacogenetics of CYP2C19: f ...... ns of a new variant CYP2C19*17
@en
type
label
Pharmacogenetics of CYP2C19: f ...... ns of a new variant CYP2C19*17
@ast
Pharmacogenetics of CYP2C19: f ...... ns of a new variant CYP2C19*17
@en
prefLabel
Pharmacogenetics of CYP2C19: f ...... ns of a new variant CYP2C19*17
@ast
Pharmacogenetics of CYP2C19: f ...... ns of a new variant CYP2C19*17
@en
P2093
P2860
P1476
Pharmacogenetics of CYP2C19: f ...... ns of a new variant CYP2C19*17
@en
P2093
Alain Li-Wan-Po
Candy Cooley
James Lithgow
Peter Farndon
Thierry Girard
P2860
P304
P356
10.1111/J.1365-2125.2009.03578.X
P407
P577
2010-03-01T00:00:00Z